<DOC>
	<DOCNO>NCT02082457</DOCNO>
	<brief_summary>This trial investigate efficacy safety YKP10811 Subjects With Irritable Bowel Syndrome With Constipation . The difference responder rate test group ( 10 , 20 40mg ) placebo evaluate .</brief_summary>
	<brief_title>Efficacy Safety YKP10811 Subjects With Irritable Bowel Syndrome With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1. 18 year old 2. patient meet ROME III criterion Ctype IBS pregnancy lactation history surgery gastrointestinal tract history gastrointestinal bleeding , diverticulitis ileus within 1 year screen visit inflammatory bowel disease malignant tumor within 5 year screen visit take drug could impact efficacy assessment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Constipation</keyword>
	<keyword>C-IBS</keyword>
</DOC>